TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

XALATAN

LATANOPROST
Cardiovascular Approved 1996-06-05
2
Indications
--
Phase 3 Trials
2
Priority Reviews
29
Years on Market

Details

Status
Prescription
First Approved
1996-06-05
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: LATANOPROST

XALATAN Approval History

Loading approval history...

What XALATAN Treats

2 indications

XALATAN is approved for 2 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Glaucoma
  • Ocular Hypertension
Source: FDA Label

Drugs Similar to XALATAN

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALPHAGAN P
BRIMONIDINE TARTRATE
2 shared
AbbVie
Shared indications:
GlaucomaOcular Hypertension
BETAGAN
LEVOBUNOLOL HYDROCHLORIDE
2 shared
AbbVie
Shared indications:
GlaucomaOcular Hypertension
BETOPTIC
BETAXOLOL HYDROCHLORIDE
2 shared
Novartis
Shared indications:
GlaucomaOcular Hypertension
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE
BRIMONIDINE TARTRATE
2 shared
UPSHER SMITH LABS
Shared indications:
GlaucomaOcular Hypertension
COMBIGAN
BRIMONIDINE TARTRATE
2 shared
AbbVie
Shared indications:
GlaucomaOcular Hypertension
COSOPT
DORZOLAMIDE HYDROCHLORIDE
2 shared
THEA PHARMA
Shared indications:
GlaucomaOcular Hypertension
COSOPT PF
DORZOLAMIDE HYDROCHLORIDE
2 shared
THEA PHARMA
Shared indications:
GlaucomaOcular Hypertension
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
DORZOLAMIDE HYDROCHLORIDE
2 shared
BAUSCH AND LOMB
Shared indications:
GlaucomaOcular Hypertension
DURYSTA
BIMATOPROST
2 shared
AbbVie
Shared indications:
GlaucomaOcular Hypertension
IYUZEH
LATANOPROST
2 shared
THEA PHARMA
Shared indications:
GlaucomaOcular Hypertension
SIMBRINZA
BRIMONIDINE TARTRATE
2 shared
Novartis
Shared indications:
GlaucomaOcular Hypertension
TIMOLOL
TIMOLOL
2 shared
SOMERSET
Shared indications:
GlaucomaOcular Hypertension
TRAVATAN Z
TRAVOPROST
2 shared
Novartis
Shared indications:
GlaucomaOcular Hypertension
ACETAZOLAMIDE
ACETAZOLAMIDE
1 shared
MANKIND PHARMA
Shared indications:
Glaucoma
AZOPT
BRINZOLAMIDE
1 shared
Novartis
Shared indications:
Ocular Hypertension
BETOPTIC S
BETAXOLOL HYDROCHLORIDE
1 shared
Novartis
Shared indications:
Ocular Hypertension
BRINZOLAMIDE
BRINZOLAMIDE
1 shared
BAUSCH AND LOMB
Shared indications:
Ocular Hypertension
IDOSE TR
TRAVOPROST
1 shared
GLAUKOS
Shared indications:
Ocular Hypertension
ISTALOL
TIMOLOL MALEATE
1 shared
BAUSCH AND LOMB
Shared indications:
Ocular Hypertension
LATANOPROSTENE BUNOD
LATANOPROSTENE BUNOD
1 shared
GLAND
Shared indications:
Ocular Hypertension
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XALATAN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

XALATAN is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. XALATAN is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.